HPS files world patent for mood-enhancing compound from sea coral

Human Pheromone Sciences, Inc. has announced that it has filed a Comprehensive Patent Application with the International Bureau of the World Patent Office for the use of its innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

"We recently announced that we had filed an application with the U.S. Patent and Trademark Office for this compound, labeled as ER 303, and we have now followed-up with a patent application with the International Bureau that will cover major countries outside the United States," a spokesperson indicated. "This unique technology has worldwide applications, and, as such, we are also seeking to protect its value in Europe and other primary consumer markets outside the United States. Seeking this protection is critical in that we are seeking licensing opportunities with companies having a worldwide marketing and product presence." The Company reiterated that prior to its reproduction of this compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.

The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates. An HPS spokesperson indicated that the Company believes that this additional filing on its new compound should be of interest to the major consumer products companies around the world.

This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10- KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
A Story of Innovative Molecules: From Machines to Cyclic Compounds